Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  2. 7

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  3. 8

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  4. 9

    S. Korea votes in favor of Palestinian bid for UN membership

    S. Korea votes in favor of Palestinian bid for UN membership
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
지나쌤

Hanmi Pharma delays phase 3 trials of diabetes treatments until 2017

By 박한나

Published : Oct. 28, 2016 - 11:27

    • Link copied

[THE INVESTOR] South Korea’s Hanmi Pharmaceutical will embark on Phase 3 clinical trials of its long-acting diabetes treatments in 2017, the company said on Oct. 27. 


The late-stage study on so-called GLP-1 diabetes treatments, which was initially set to begin in the fourth quarter this year, was delayed as production of the drug fell behind schedule, according to the drug maker.

In 2015, French pharmaceutical firm Sanofi obtained an exclusive worldwide license to develop and commercialize the treatment. Hanmi retained an exclusive option to co-commercialize the products in Korea and China.

Shares in Hanmi fell 2.2 percent, or 9,000 won (US$7.86) to trade at 400,000 won as of 10:40 a.m.

By Park Han-na (hnpark@heraldcorp.com)

More from Headlines